COVID-19 in children: clinical and epidemiological spectrum in the community

César García-Vera1, Sandra Castejón-Ramírez2, Elena Laín Miranda3

  • 1Primary Health Care Center "José Ramón Muñoz Fernández", Zaragoza, Spain. cgarciavera@gmail.com.

Insights

Pediatric COVID-19 in Spain, diagnosed with widespread testing, revealed mild symptoms in over half of cases. Transmission primarily occurred within families, with rare severe outcomes in children under 15.

Area of Science:

  • Epidemiology
  • Infectious Diseases
  • Pediatrics

Background:

  • Early pediatric COVID-19 studies in Spain were limited by diagnostic tool availability.
  • Previous research focused on initial pandemic phases, potentially underrepresenting the infection's true spectrum.
  • Widespread diagnostic access is crucial for accurate pediatric SARS-CoV-2 epidemiology.

Purpose of the Study:

  • To determine the real-world spectrum of pediatric COVID-19 in Aragón, Spain.
  • To analyze infection epidemiology, clinical presentation, and outcomes in children aged 0-14 years.
  • To assess the impact of enhanced diagnostic capabilities on case detection.

Main Methods:

  • A descriptive and analytical observational study of pediatric cases (0-14 years) in Aragón from May to October 2020.
  • Diagnosis via PCR, rapid antigen tests, or positive IgG serology.
  • Inclusion of cases identified through symptoms and contact tracing.

Main Results:

  • 5933 positive pediatric cases were identified; 50.3% were asymptomatic.
  • Family environment was the primary source of infection (67.8%).
  • Fever and cough were most common symptoms; hospitalizations (0.52%), ICU admissions (0.05%), and one death (0.02%) were rare. Infants (<1 year) showed higher symptom and hospitalization rates.

Conclusions:

  • SARS-CoV-2 infection in children under 15 resembles other mild respiratory viral infections.
  • High asymptomatic rates, predominantly family-based transmission, mild symptoms, and infrequent complications characterize pediatric COVID-19.
  • Enhanced diagnostics improved the understanding of pediatric SARS-CoV-2 epidemiology and clinical manifestations.

Related Concept Videos

COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
741
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
56
Prevalence and Incidence01:08

Prevalence and Incidence

In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
1.0K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
44
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
39